Durablate catheter results demonstrate feasibility in VT ablation

717

Thermedical has announced that results from a first-in-human early feasibility study (EFS) using the Durablate catheter to treat ventricular tachycardia (VT) were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) 2020 Science online meeting.

Titled the Saline Enhanced Radiofrequency (SERF) VT Ablation EFS, preliminary results were presented by the study’s Lead Investigator, Douglas L Packer, professor of medicine at the Mayo Clinic (Rochester, USA), on Heart Rhythm 365, the society’s digital education platform.

“Our data from the first-in-human EFS suggest a highly feasible approach to treating patients with recurrent VT that is resistant to other treatments,” said Packer.

The SERF VT EFS is a single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT, a leading cause of sudden cardiac death worldwide. The target study population consists of patients who have failed all current forms of treatment including implantable cardioverter defibrillators (ICDs), medical therapy and other forms of ablation therapy. The Durablate catheter uses a needle electrode to deliver heated, degassed saline and radiofrequency energy into the tissue to more effectively treat the tissue causing the VT than a standard, conventional ablation catheter.

Early feasibility results of 32 patients treated at six centres in the USA and Canada indicate that the SERF Durablate catheter is highly effective at eliminating clinical VT in patients with an acute procedural success rate of 100 percent and shows acceptable initial safety.

Five-month follow-up data demonstrate that more than half of the patients had no recurrent VT and more than 60 percent of the patients had their VT reduced by 90% or more. In contrast, for the six months prior to ablation, patients had a median of 40 ICD treatments (shock or antitachycardia pacing), which can significantly reduce quality of life. The Durablate catheter was used to deliver an average of 10 lesions per case and the average total procedure time was four hours and 42 minutes, which is significantly shorter than typical conventional RF procedures for patients of this nature.

“We are extremely encouraged by these early results as it puts us one step closer to advancing treatment that can reduce or eliminate VT episodes in patients,” said Michael Curley co-founder and chief executive officer of Thermedical. “Moreover, a successful and effective method to treat VT that is drastically shorter and more effective than current ablation procedures would improve quality of life considerably for people who develop, or who are at high risk of developing VT every year.”

The SERF VT EFS is underway in the USA at Mayo Clinic, Loyola University Medical Center, and Vanderbilt University Medical Center, and in Canada at Southlake Regional Health Centre, Montreal Heart Institute and Quebec Heart and Lung Institute.


LEAVE A REPLY

Please enter your comment!
Please enter your name here